Show Summary Details
Page of

Neuroendocrine tumour 

Neuroendocrine tumour
Neuroendocrine tumour

Gaurav Kapur

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 19 January 2021

Neuroendocrine gastro-entero-pancreatic tumours (NET) constitute a heterogeneous group of tumours arising from the neuroendocrine cells of the embryological gut. Histological diagnosis is mandatory and these tumours express immunoreactivity to panendocrine markers (e.g. chromogranin A and synaptophysis. Curative resection of the primary tumour and locoregional nodal metastases improves survival in localised disease. Even in advanced/metastatic disease, cytoreductive surgery should be considered when metastatic disease is localised or if >70% of tumour can be resected, which might improve symptoms and response to systemic therapy. Somatostatin analogs are the medical treatment of choice in function NETs. Chemotherapy has a role in metastatic grade 2/3 tumours and inoperable liver progressive liver disease. Peptide receptor targeted radiotherapy has an established role in a subset of patients. Role of TKI and mTOR inhibitors is evolving.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.